Oramed Pharmaceuticals (ORMP) 10-K2022 FY Annual report

Filed: 6 Mar 23, 5:01pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Good

New words: abate, ABIM, Acumen, add, addendum, Aldeyra, alliance, Anne, Aon, Asia, asymptomatic, Athira, attention, attrition, Australia, background, benchmark, Bernardo, bid, BioLine, Biopharma, blend, Brazilian, breakdown, Bribery, capable, Caspi, chair, Chamonix, Chancery, Chicago, choose, Clinician, cohesive, College, Collplant, Colombia, complaint, Compugen, confirmatory, consortium, constitutionality, Corrupt, counsel, cyber, cyberattack, damage, delisted, delisting, Deloitte, departure, depressing, Derovan, devoting, Diasome, difficulty, discontinue, discontinued, dismissed, drop, dropout, dropped, EASD, Edge, electrical, Eliem, engineering, Enlivex, Enochian, EU, fatigue, fewer, fluid, fold, FRCP, Gamida, Gel, GoldenTree, Goldfarb, goodwill, Guaranty, guide, guideline, gym, hand, Head, headed, Houssay, ID, identical, immune, immunogenicity, imperative, inappropriate, inconclusive, incurrence, Indonesia, injury, inside, intrusion, JDRF, Kamada, Kazakhstan, Keck, Korea, Laureate, LLB, Malaysia, malware, media, Medicox, Mexico, Midwest, mild, morale, Netanel, noncompliance, nonpublic, Northwestern, notwithstanding, occasion, offsite, Oman, optimal, Optum, Panel, Pennsylvania, penny, Pharma, plaintiff, PolyPid, possession, predominant, presence, Pritzker, pro, promising, proven, qualitative, Rallybio, rata, Redhill, regain, remeasured, replicate, replicated, Repositioning, reproduce, reputation, reputational, residency, revaluation, round, Rozov, Russia, rx, SAPHRA, satisfactorily, Seligman, Shnida, side, Singapore, slower, Society, Sol, sophistication, Southeast, Southern, speculation, Stanford, stemming, summa, Supreme, Switzerland, Syncora, Tan, telecommunication, Terrace, Thailand, Thanh, top, trademark, trend, Turkey, UBS, UCLA, Ukraine, unanticipated, undertaken, unified, unintended, Union, upheld, Urogen, USC, Uzbekistan, Velocity, Verastem, vi, viability, viable, Vietnam, view, viewed, vii, viii, Viking, VistaGen, VLP, vulnerable, war, weaker, Werewolf, Wharton, workplace, worthwhile, writing, wrongdoing, Yadin, Zomedica

Removed: absence, acquirer, adjustment, affiliated, aggregated, Ariel, arm, Avraham, BioHealing, bloodstream, Commerce, complement, concept, consumer, DeFronzo, deploying, Diaspora, Discouraging, discrepancy, effort, Emisphere, enable, excellent, extension, flagship, FPG, frequency, Gabay, Gao, glucagon, graduate, Green, HighCape, hypoglycemic, IIb, Impeding, incretin, Incubation, inflammatory, innovator, interaction, investigate, Investigational, Jersey, joining, knowledgeable, leptin, likelihood, Maayan, merger, mineral, Minister, MMTT, modest, move, MSA, Nevada, NIH, nonalcoholic, NY, opposite, overview, partnering, passage, pediatric, pharmacokinetic, physiological, plc, Point, portal, PPG, premier, Prime, proof, Rahway, recommended, recruited, Regenerative, reincorporated, remining, rest, resulted, revolutionizing, Rhythmia, Rosetta, secretion, select, Sharon, Shire, significance, statistically, substantiate, takeover, tender, thrice, tiered, titrated, tolerance, tract, treated, twelve, undergraduate, undiluted, vein, Xiaoming

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ORMP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 10.13

Second Amendment to Employment Agreement

This Second Amendment to Employment Agreement (this “Second Amendment”) is entered into as of this 25th day of October 2022 and is effective as of January 1, 2023, by and between David Silberman, an individual residing in Jerusalem, Israel (the “Executive”), and Oramed Ltd., a company incorporated under the laws of the State of Israel, with an address at 20 Mamilla Ave., Jerusalem, Israel 9414904 (the “Company”).

WHEREAS, the Company and the Executive entered into an employment agreement, dated as of May 23, 2021, as amended effective September 1, 2022 (the “Employment Agreement”); and

WHEREAS, Company and the Executive desire to amend the terms and conditions of the Employment Agreement to increase the Executive’s salary.

NOW, THEREFORE, the Company and the Executive agree as follows:

In Section 2.1(a) of the Employment Agreement - Salary, the following paragraph is hereby added:

As of January 1, 2023, the Executive shall be entitled to a gross monthly salary of NIS 47,438 (the “Salary”).

Except for the changes and/or additions stated herein, all the other terms of the Employment Agreement shall remain valid and bind the parties without any change. In the case of a contradiction between the provisions of this Second Amendment and the provisions of the Employment Agreement, the provisions of this Second Amendment shall prevail. Without limiting the generality of the foregoing, the term “Agreement” as used in the Employment Agreement shall be deemed to be the Employment Agreement as amended by this Second Amendment.

IN WITNESS WHEREOF, the parties have executed this Second Amendment to Employment Agreement as of October 25, 2022.

	Oramed Ltd.

	/s/ Nadav Kidron
	Nadav Kidron, CEO

	/s/ David Silberman
	David Silberman